SGRQ | SF-36 | |||||||
---|---|---|---|---|---|---|---|---|
Symptoms | Activity | Impacts | Total | PCS | MCS | RCS | ||
SGRQ | Symptoms | |||||||
Activity | 0.51§ | |||||||
Impacts | 0.68§ | 0.67§ | ||||||
Total | 0.77§ | 0.88§ | 0.91§ | |||||
SF-36 | PCS | −0.44§ | −0.73§ | −0.60§ | −0.70§ | |||
MCS | −0.32‡ | −0.27† | −0.28† | −0.29† | 0.08 | |||
RCS | −0.28† | −0.42§ | −0.40§ | −0.44§ | 0.25* | 0.15 | ||
6WMT | 6MWD | −0.27† | −0.54§ | −0.32† | −0.44§ | 0.39§ | 0.08 | 0.20* |
Initial SpO2 | 0.0002 | −0.12 | −0.08 | −0.09 | 0.05 | −0.15 | −0.09 | |
Lowest SpO2 | −0.15 | −0.14 | −0.21 | −0.19 | 0.10 | −0.01 | −0.05 | |
Initial HR | 0.16 | 0.03 | 0.15 | 0.11 | −0.09 | 0.03 | −0.06 | |
Final HR | 0.11 | −0.04 | 0.04 | 0.03 | 0.07 | 0.00 | −0.02 | |
FBS | 0.34‡ | 0.56§ | 0.54§ | 0.58§ | −0.50§ | −0.17 | −0.24* | |
DSP | −0.29† | −0.55§ | −0.33‡ | −0.46§ | 0.40§ | 0.06 | 0.19 | |
DA | 0.14 | 0.12 | 0.19 | 0.17 | −0.09 | 0.04 | 0.07 | |
Clinical parameters | Age | 0.09 | 0.45§ | 0.22* | 0.36‡ | −0.51§ | 0.10 | −0.18 |
Disease duration | 0.16 | 0.13 | 0.11 | 0.18 | −0.06 | − 0.02 | −0.01 | |
BMI | −0.30† | −0.08 | − 0.27† | −0.22* | 0.14 | 0.07 | 0.20* | |
CCI | −0.09 | 0.33‡ | 0.13 | 0.19 | −0.35‡ | 0.04 | −0.05 | |
%FVC | −0.41§ | −0.28† | − 0.43§ | −0.43§ | 0.15 | −0.03 | 0.07 | |
%FEV1 | −0.34‡ | −0.26† | − 0.32‡ | −0.35‡ | 0.07 | −0.03 | − 0.003 |